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Gastroenteropancreatic neuroendocrine tumors are the most incident neuroendocrine tumors. In the new WHO
classification (2010) the embryological derivation of each neoplastic entity is one of the most important parameters.
Gangliocytic Paraganglioma is a tumor originating in the hindgut, a rare neoplasm, generally affecting the second
portion of the duodenum, the majority of which are benign.
Cases of gangliocytic paraganglioma with local metastasis or local recurrence have also been reported.
We describe a GP in a 48-year-old caucasian male with an unusual site (4th portion of duodenum) and an interesting
immunohistochemical and molecular pattern. In particular, we examined the expression of some neuroendocrine
markers and a marker of neuronal differentiation, NeuroD1, whose expression can help to better understand the nature
of this neoplasia.
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Gangliocytic paraganglioma (GP) is a rare gastrointes-
tinal tumor of uncertain histogenesis, with immunohis-
tochemical features of neuroendocrine type.
This neoplasia, in the context of the new WHO classifi-
cation (2010) of Gastroenteropancreatic neuroendocrine
(GEP-NET) tumors is classified as tumor derived from the
hindgut [1].
Usually, it is located in the second part of the duodenum
and, in a few cases, in the esophagus, jejunum, pylorus,
pancreas and upper mediastinum and is characterized by
benign clinical behavior and a favorable outcome.
However, recent studies have highlighted the presence
of paraganglioma in other sites, particularly in the
retroperitoneum [2], with a case that metastasizes to
the vertebra [3].* Correspondence: monicantile@libero.it
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unless otherwise stated.Moreover, cases of regional lymph node metastasis
and local recurrence have been reported, suggesting a
potential malignant progression of this tumor [4,5].
Histologically GP is a triphasic neoplasia. It is com-
posed of three cellular types: epithelioid, ganglion and
spindle cells, whose identification is supported by immu-
nohistochemical (IHC) detection of neuronal and neuro-
endocrine markers (synaptophysin, chromogranin A,
CD56, S-100, NSE and Somatostatin) [6].
Currently, the only prognostic marker for neuroendo-
crine tumors is Ki67 index expression associated with mi-
totic index. Molecular markers indicative of poor prognosis
have not yet been identified.
Recently, a new marker, NeuroD1 (Neurogenic Differen-
tiation 1), has been shown to act as a neuronal differenti-
ation factor. NeuroD1 is a transcription factor originally
identified in beta pancreatic cells and it is able to convert
epithelial cells into neurons in Xenopus Embryos [7].
Moreover, NeuroD1 has been identified as a new neuroen-
docrine marker in GEP-NET and prostate cancer (pCA).
In GEP-NET its expression seems to be related toral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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http://www.diagnosticpathology.org/content/9/1/54differentiation degree [8], while in pCA its expression is
more frequent than Chromogranin A [9,10]. Cytoplasmic
positive staining for NeuroD1 was also strongly associated
with MPI (microscopic perineural invasion).
In this report we present a case of Gangliocytic paragan-
glioma on which some neuroendocrine markers (Syn,
CgA, CD56, NSE) and NeuroD1 expression have been
tested by IHC. On the same sample NeuroD1 expression
has also been determined by quantitative Real Time PCR.
Case presentation
GP shows evidence of neuronal differentiation, also sup-
ported by cell positivity for several neuroendocrine (ND)
markers.
In this case, a 48-year-old caucasian man was referred to
our Institution after recurrent upper GI bleeding with
melena. The patient reported a four month history of
intermittent coffee ground stools, fatigue and weight loss.
Clinical examination was uneventful and the patient was
hemodinamically stable with 8.4 g/dl value of Haemoglo-
bin and a Hematocrit of 28%. Iron deficiency was also
present. No history of previous pathologies was reported.
Pan-colonoscopy was negative and a standard gastroscopy
had been performed at another Institution, revealing a
4 cm bulky mass of the distal duodenum. Gastroscopy was
repeated in our institution with pediatric instrument to
have a better evaluation of the mass. The lesion, located in
the 4th duodenal portion, was included in the duodenalFigure 1 H&E: A) panoramic view with epithelioid and ganglion cells
C) panoramic view with epithelioid, spindle and ganglion cells (10X);wall and covered with normal mucosa with a bleeding sur-
face. Multiple biopsies were performed but the results
were inconclusive.
A CT-scan was also performed, revealing a thickening
of the 4th portion of the duodenal wall and non-
lymphadenopathies.
The patient underwent an exploratory laparotomy
with segmental resection of the 4th portion of the duo-
denum and the first jejunal loop. An end to end anasto-
mosis between the 4th duodenal portion and the jejunum
was carried out. The patient was discharged on the 6th
post-operative day after an uneventful course.
Twenty-four months after surgery, the patient was di-
agnosed disease free.
Macroscopically the surgical specimen showed a polyp-
oid lesion, covered with smooth mucosa with microero-
sion area, of 4 cm × 4 cm × 3 cm. All tumor samples were
stained with H/E (hematoxilin/eosin). IHC stains were
then performed.
Under microscopic observation the tumor was com-
posed of epithelioid cell nests, areas of spindle cells and
scattered ganglion cells (Figure 1). The neoplastic prolif-
eration affected submucosal layers up to the lamina pro-
pria and was covered with duodenal mucosa devoid of
morphological abnormalities, with focal areas of erosion
of the epithelial layer.
The panel of immunohistochemical markers used
showed a negative cellular reaction for cytokeratin (CK) 7(4X); B) high magnification of epithelioid cellular elements (20X);
D) high magnification of ganglion cells (20X).
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http://www.diagnosticpathology.org/content/9/1/54(Dako, OVTL 12/30, 1: 200), CK20 (Dako, Ks20.8, 1:50),
CDX2 (Dako, DAK-CDX2, 1:50) and CD117 (Dako,
CD117, 1:50). A low positive cellular reaction was present
for Vimentin (NeoMarkers, Westinghouse, California,
D9, 1:1000.), S100 (Dako, 1:3000), Chromogranin A (Dako,
A0430, 1:1500) and Somatostatin (Abcam, ab103790,
1:200) while a strong positive cellular reaction was
detected for Synaptophysin (Dako,1:3000), CD56 (Dako,
123C3, 1:50) and NSE (Dako, BBS/NC/VI-H14, 1:100)
(Figure 2).
The final histological examination revealed a GP tumor.
After histological diagnosis, we evaluated the expres-
sion by IHC of NeuroD1 marker with primary antibody
against human NeuroD1(Abcam, ab60704,1:200) for one
hour of incubation. The sections were rinsed in TBS and
incubated for 20 min with Novocastra Biotinylated Sec-
ondary Antibody (RE7103), a biotin-coniugated secondaryFigure 2 Immunostaining: A) Low expression (< 2%) of ki67 (10X); B)
expression of CgA (10X); D) Low/Moderate expression of Somatostati
expression of S100 protein in spindle cells (10X).antibody formulation that recognize mouse and rabbit
immunoglobulins.
The sections were then rinsed in TBS and incubated
for 20 min with Novocastra Streptavidin-HRP (RE104).
Peroxidase reactivity was visualized using a 3,3′-diami-
nobenzidine (DAB).
IHC staining of Neuro D1 was scored as follows: − , if <
5% of tumor cells were stained; +, if there were focal, weak
tumor cells staining; ++, if there were moderate tumor cells
staining; +++, if there were marked tumor cells staining.
NeuroD1 showed a marked positivity (+++), (Figure 3)
mostly cytoplasmic, especially in ganglion and epithelioid
cells.
Finally, for gene expression analysis, total RNA was
isolated from a frozen biopsy of the tumor stored in our
Institutional Bio-Bank, using RNeasy Mini Kit (Qiagen
GmbH, Hilden, Germany) following the manufacturer’sHigh expression of CD56 in epithelioid cells (10X); C) low
n (20X); E) High expression of Synaptophysin (10X); F) High
Figure 3 Neuro D1 immunostaining: A) cytoplasmic positivity in epithelioid and ganglion cells (4X); B) cytoplasmic positivity in
epithelioid cells (40X).
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DNase (Qiagen GmbH, Hilde, Germany) to prevent
amplification of genomic DNA. A total of 1 mg RNA
was subjected to cDNA synthesis. Quantitative Real
Time -PCR (qRT PCR) was performed in a Light Cycler
system (Roche Molecular Biochemicals, Mannheim,
Germany) using specific TaqMan Gene Expression As-
says for human NeuroD1 (Real Time Designer Assay
cod. 05583055001, Roche Molecular Biochemicals).
qRT PCR analysis showed NeuroD1 over-expression com-
pared to other cancer samples used as controls (Figure 4).
Discussion
GP is a rare neuroendocrine tumor of the digestive tract
(GEP-NET ), originating in the hindgut, and mainly lo-
cated at the second portion of the duodenum. It is usually
benign.
Histopathological diagnosis of the disease requires the
detection of a triphasic pattern of growth, represented
by three cellular components: epithelioid cells, spindle
shaped cells and ganglion-like cells [1].
The majority of the reported cases of duodenal GP has
been of benign nature, even if some cases in literatureFigure 4 Real time PCR expression of NeuroD1: 1) pancreatic normal
4) GP sample. All reactions were performed in triplicate and data are exprshowed the presence of regional lymph nodes metas-
tasis [5]. Distant metastases have not been observed.
Radical surgery with lymph node dissection is there-
fore required.
In the new WHO classification of NET(2010), the only
parameter of prognostic value is represented by Ki67 index
expression.
The case reported in this paper was characterized by a
sessile polypoid lesion that at routine histopathological
examination was diagnosed as duodenal GP, with negativ-
ity for CK 7 and CK 20 and with positivity for several neu-
roendocrine markers.
Since the identification of new molecular markers of
both diagnostic and prognostic value becoming increas-
ingly necessary, we decided to evaluate the expression of
another neuroendocrine marker, NeuroD1, recently de-
scribed in GEP-NET and other malignancies.
Our data, derived from immunohistochemistry, con-
firmed the positive protein expression of the NeuroD1
marker in this case of GP. Furthermore, we have also de-
termined NeuroD1 gene expression on the same fresh
cryopreserved sample, showing even in this case an over-
expression of the marker.sample; 2) pancreatic tumor sample; 3) prostatic tumor sample;
essed as mean of relative amount of mRNAs levels.
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very rare tumor, could complete the panel of neuroendo-
crine markers for the diagnosis of these tumors.
Moreover, NeuroD1 may be identified on a largest
casuistry of NETs to verify its role in the pathogenesis of
these malignancies.
Conclusions
Even if GP follows a benign course and invasive growth
patterns and lymph node metastasis are rare events, the
identification of new molecular markers markers associ-
ated with its neuroendocrine differentiation, is necessary.
In this context, Neuro D1 could be an important element
also for the development of more tailored therapies for pa-
tients with this disease, as already described for other neu-
roendocrine tumors [11-13].
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